VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q126289807 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000005.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q126289807‏
035 ‎‡a (OCoLC)Q126289807‏
043 ‎‡c NZ‏
046 ‎‡f 19400000‏
100 0 ‎‡a John P. V. Collins‏ ‎‡c New Zealand breast surgeon‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a John Collins‏ ‎‡9 eo‏ ‎‡9 scn‏ ‎‡9 co‏ ‎‡9 io‏ ‎‡9 af‏ ‎‡9 vmf‏ ‎‡9 vi‏ ‎‡9 ca‏ ‎‡9 it‏ ‎‡9 an‏ ‎‡9 eu‏ ‎‡9 cy‏ ‎‡9 gd‏ ‎‡9 pt-br‏ ‎‡9 ga‏ ‎‡9 zu‏ ‎‡9 cs‏ ‎‡9 et‏ ‎‡9 gl‏ ‎‡9 ie‏ ‎‡9 id‏ ‎‡9 es‏ ‎‡9 en-gb‏ ‎‡9 lb‏ ‎‡9 wa‏ ‎‡9 nn‏ ‎‡9 min‏ ‎‡9 nb‏ ‎‡9 pms‏ ‎‡9 tr‏ ‎‡9 nap‏ ‎‡9 lij‏ ‎‡9 li‏ ‎‡9 wo‏ ‎‡9 lt‏ ‎‡9 frp‏ ‎‡9 nds-nl‏ ‎‡9 br‏ ‎‡9 rm‏ ‎‡9 ro‏ ‎‡9 ia‏ ‎‡9 sr-el‏ ‎‡9 pcd‏ ‎‡9 vec‏ ‎‡9 kab‏ ‎‡9 sco‏ ‎‡9 nrm‏ ‎‡9 ast‏ ‎‡9 hr‏ ‎‡9 bm‏ ‎‡9 de‏ ‎‡9 hu‏ ‎‡9 rgn‏ ‎‡9 da‏ ‎‡9 fr‏ ‎‡9 prg‏ ‎‡9 mi‏ ‎‡9 fi‏ ‎‡9 vls‏ ‎‡9 vo‏ ‎‡9 kg‏ ‎‡9 en-ca‏ ‎‡9 jam‏ ‎‡9 mg‏ ‎‡9 bar‏ ‎‡9 pt‏ ‎‡9 gsw‏ ‎‡9 sc‏ ‎‡9 fur‏ ‎‡9 sw‏ ‎‡9 sv‏ ‎‡9 de-ch‏ ‎‡9 frc‏ ‎‡9 sk‏ ‎‡9 pap‏ ‎‡9 oc‏ ‎‡9 ms‏ ‎‡9 de-at‏ ‎‡9 nds‏ ‎‡9 nl‏ ‎‡9 pl‏
670 ‎‡a Author's Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII‏
670 ‎‡a Author's Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.‏
670 ‎‡a Author's Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results‏
670 ‎‡a Author's Delay in seeking medical care for self-detected breast symptoms in New Zealand women‏
670 ‎‡a Author's Hormone replacement therapy and breast cancer, revisited‏
670 ‎‡a Author's Hormones and breast cancer: should practice be changed?‏
670 ‎‡a Author's Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.‏
670 ‎‡a Author's Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93‏
670 ‎‡a Author's Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?‏
670 ‎‡a Author's Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials‏
670 ‎‡a Author's Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century‏
670 ‎‡a Author's Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Bre‏
670 ‎‡a Author's Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.‏
670 ‎‡a Author's The relationship of symptoms and psychological factors to delay in seeking medical care for breast symptoms‏
919 ‎‡a hormonesandbreastcancershouldpracticebechanged‏ ‎‡A Hormones and breast cancer: should practice be changed?‏ ‎‡9 1‏
919 ‎‡a adjuvantchemotherapyfollowedbygoserelincomparedwitheithermodalityalonetheimpactonamenorrheahotflashesandqualityoflifeinpremenopausalpatientstheinternationalbreastcancerstudygrouptrial8‏ ‎‡A Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII‏ ‎‡9 1‏
919 ‎‡a decreasedimmunoreactivityforp27proteininpatientswithearlystagebreastcarcinomaiscorrelatedwithher2neuoverexpressionandwithbenefitfrom1courseofperioperativechemotherapyinpatientswithnegativelymphnodestatusresults‏ ‎‡A Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results‏ ‎‡9 1‏
919 ‎‡a delayinseekingmedicalcareforselfdetectedbreastsymptomsinnewzealandwomen‏ ‎‡A Delay in seeking medical care for self-detected breast symptoms in New Zealand women‏ ‎‡9 1‏
919 ‎‡a hormonereplacementtherapyandbreastcancerrevisited‏ ‎‡A Hormone replacement therapy and breast cancer, revisited‏ ‎‡9 1‏
919 ‎‡a isadjuvantchemotherapyofbenefitforpostmenopausalwomenwhoreceiveendocrinetreatmentforhighlyendocrineresponsivenodepositivebreastcancerinternationalbreastcancerstudygrouptrials7and1293‏ ‎‡A Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.‏ ‎‡9 1‏
919 ‎‡a ischemotherapynecessaryforpremenopausalwomenwithlowerrisknodepositiveendocrineresponsivebreastcancer10yearupdateofinternationalbreastcancerstudygrouptrial1193‏ ‎‡A Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93‏ ‎‡9 1‏
919 ‎‡a ki67expressioninbreastcarcinomaitsassociationwithgradingsystemsclinicalparametersandotherprognosticfactorsasurrogatemarker‏ ‎‡A Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?‏ ‎‡9 1‏
919 ‎‡a oculartoxicityduringadjuvantchemoendocrinetherapyforearlybreastcancerresultsfrominternationalbreastcancerstudygrouptrials‏ ‎‡A Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials‏ ‎‡9 1‏
919 ‎‡a patternsofrecurrenceofearlybreastcanceraccordingtoestrogenreceptorstatusatherapeutictargetforaquarterofacentury‏ ‎‡A Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century‏ ‎‡9 1‏
919 ‎‡a prognosticvalueofextracapsulartumorspreadforlocoregionalcontrolinpremenopausalpatientswithnodepositivebreastcancertreatedwithclassicalcyclophosphamidemethotrexateandfluorouracillongtermobservationsfrominternationalbre‏ ‎‡A Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Bre‏ ‎‡9 1‏
919 ‎‡a siteofprimarytumorhasaprognosticroleinoperablebreastcancertheinternationalbreastcancerstudygroupexperience‏ ‎‡A Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.‏ ‎‡9 1‏
919 ‎‡a relationshipofsymptomsandpsychologicalfactorstodelayinseekingmedicalcareforbreastsymptoms‏ ‎‡A The relationship of symptoms and psychological factors to delay in seeking medical care for breast symptoms‏ ‎‡9 1‏
919 ‎‡a adjuvantendocrinetherapycomparedwithnosystemictherapyforelderlywomenwithearlybreastcancer21yearresultsofinternationalbreastcancerstudygrouptrial4‏ ‎‡A Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
947 ‎‡a NZ‏ ‎‡9 1‏
996 ‎‡2 LC|no2006072871‏
996 ‎‡2 LC|n 2008067873‏
996 ‎‡2 ISNI|0000000033600265‏
996 ‎‡2 ISNI|0000000042349957‏
996 ‎‡2 LC|nr 91023585‏
996 ‎‡2 PLWABN|9814147056505606‏
996 ‎‡2 NII|DA05716167‏
996 ‎‡2 ISNI|0000000038741032‏
996 ‎‡2 LC|n 2017053051‏
996 ‎‡2 NTA|068680201‏
996 ‎‡2 SUDOC|035217073‏
996 ‎‡2 DBC|87097919200914‏
996 ‎‡2 DE633|pe30012149‏
996 ‎‡2 BIBSYS|90231598‏
996 ‎‡2 NII|DA05043259‏
996 ‎‡2 LC|n 82127339‏
996 ‎‡2 ISNI|0000000113620194‏
996 ‎‡2 SUDOC|060341505‏
996 ‎‡2 LC|n 81065012‏
996 ‎‡2 PLWABN|9810660090805606‏
996 ‎‡2 LC|nr 92006110‏
996 ‎‡2 LC|n 90677130‏
996 ‎‡2 BIBSYS|90338368‏
996 ‎‡2 BNF|16214480‏
996 ‎‡2 NTA|330353454‏
996 ‎‡2 DNB|1246803771‏
996 ‎‡2 N6I|vtls000064826‏
996 ‎‡2 DNB|118087142‏
996 ‎‡2 ISNI|0000000497220172‏
996 ‎‡2 NII|DA07926262‏
996 ‎‡2 NTA|41974245X‏
996 ‎‡2 DNB|1147173257‏
996 ‎‡2 J9U|987007448791505171‏
996 ‎‡2 N6I|vtls000037485‏
996 ‎‡2 NUKAT|n 2016177214‏
996 ‎‡2 SUDOC|104147989‏
996 ‎‡2 LC|n 2014053422‏
996 ‎‡2 LC|no 99052869‏
996 ‎‡2 NII|DA05798525‏
996 ‎‡2 N6I|vtls000061998‏
996 ‎‡2 ISNI|0000000460790446‏
996 ‎‡2 BNF|12030625‏
996 ‎‡2 LIH|LNB:BP_o__t_;=CF‏
996 ‎‡2 NII|DA11315590‏
996 ‎‡2 LC|n 79130412‏
996 ‎‡2 NII|DA04735417‏
996 ‎‡2 LC|no2016079699‏
996 ‎‡2 CAOONL|ncf10733985‏
996 ‎‡2 NLA|000035029842‏
996 ‎‡2 RERO|A021712462‏
996 ‎‡2 NII|DA19414370‏
996 ‎‡2 PTBNP|939644‏
996 ‎‡2 SUDOC|191917230‏
996 ‎‡2 NII|DA04712182‏
996 ‎‡2 NII|DA0723230X‏
996 ‎‡2 ISNI|0000000027232865‏
996 ‎‡2 NTA|075268248‏
996 ‎‡2 LC|no2015168982‏
996 ‎‡2 NSK|000316153‏
996 ‎‡2 LC|no2019041670‏
996 ‎‡2 LC|no 96035920‏
996 ‎‡2 J9U|987007425549405171‏
996 ‎‡2 CAOONL|ncf12126962‏
996 ‎‡2 LC|n 2016015022‏
996 ‎‡2 SUDOC|155413457‏
996 ‎‡2 SUDOC|148411223‏
996 ‎‡2 DNB|1157886515‏
996 ‎‡2 PTBNP|1850608‏
996 ‎‡2 LC|n 2014181793‏
996 ‎‡2 PLWABN|9810702865905606‏
996 ‎‡2 CAOONL|ncf11344518‏
996 ‎‡2 ISNI|0000000041333216‏
996 ‎‡2 LC|n 98109847‏
996 ‎‡2 BNF|12985771‏
996 ‎‡2 ISNI|0000000459551421‏
996 ‎‡2 NUKAT|n 2019033351‏
996 ‎‡2 CAOONL|ncf10014556‏
996 ‎‡2 LC|n 89134956‏
996 ‎‡2 ERRR|12605669‏
996 ‎‡2 LC|n 86851466‏
996 ‎‡2 DNB|1191197344‏
996 ‎‡2 LC|n 90641672‏
996 ‎‡2 SUDOC|060258195‏
996 ‎‡2 N6I|vtls000052983‏
996 ‎‡2 DNB|1048207803‏
996 ‎‡2 DNB|1011297442‏
996 ‎‡2 LC|no2019010788‏
996 ‎‡2 DNB|188356363‏
996 ‎‡2 LC|n 83205277‏
996 ‎‡2 NII|DA07940547‏
996 ‎‡2 LIH|LNB:CGDW;=BB‏
996 ‎‡2 ISNI|000000005082405X‏
996 ‎‡2 N6I|vtls000032437‏
996 ‎‡2 ISNI|0000000111544669‏
996 ‎‡2 LC|nb2002066411‏
996 ‎‡2 PLWABN|9810543511405606‏
996 ‎‡2 RERO|A003116981‏
996 ‎‡2 DNB|1179268253‏
996 ‎‡2 NTA|321817745‏
996 ‎‡2 LC|n 85290455‏
996 ‎‡2 RERO|A003116979‏
996 ‎‡2 N6I|vtls000083858‏
996 ‎‡2 RERO|A003116974‏
996 ‎‡2 CAOONL|ncf10114118‏
996 ‎‡2 N6I|vtls000110717‏
996 ‎‡2 LC|no2021119044‏
996 ‎‡2 NII|DA02107559‏
996 ‎‡2 LC|no 97053045‏
996 ‎‡2 LC|no 00002041‏
996 ‎‡2 CAOONL|ncf10297781‏
996 ‎‡2 ISNI|0000000118794505‏
996 ‎‡2 SUDOC|184934095‏
996 ‎‡2 BLBNB|000396577‏
996 ‎‡2 NTA|067813097‏
996 ‎‡2 SUDOC|261695444‏
996 ‎‡2 DNB|1122867573‏
996 ‎‡2 J9U|987007362166705171‏
996 ‎‡2 BIBSYS|3103209‏
996 ‎‡2 LIH|LNB:DT_y_V;=B9‏
996 ‎‡2 ISNI|0000000067774984‏
996 ‎‡2 NTA|070925577‏
996 ‎‡2 DNB|1312981636‏
996 ‎‡2 ISNI|0000000023695272‏
996 ‎‡2 CAOONL|ncf11490223‏
996 ‎‡2 SUDOC|255821441‏
996 ‎‡2 LC|n 82215388‏
996 ‎‡2 LC|nb 98091230‏
996 ‎‡2 BIBSYS|90859153‏
996 ‎‡2 LC|no2020116066‏
996 ‎‡2 BIBSYS|11043581‏
996 ‎‡2 ISNI|0000000459841808‏
996 ‎‡2 ISNI|0000000078485141‏
996 ‎‡2 SUDOC|084592176‏
996 ‎‡2 ISNI|0000000363454109‏
996 ‎‡2 DNB|1180329481‏
996 ‎‡2 ISNI|000000040925690X‏
996 ‎‡2 J9U|987007452864505171‏
996 ‎‡2 NII|DA06842280‏
996 ‎‡2 NTA|338806105‏
996 ‎‡2 N6I|vtls000356819‏
996 ‎‡2 ISNI|0000000391430964‏
996 ‎‡2 LC|n 82033924‏
996 ‎‡2 UAE|Mill_a10000596‏
996 ‎‡2 LC|no2019040010‏
996 ‎‡2 ISNI|0000000445020072‏
996 ‎‡2 LC|n 82136059‏
996 ‎‡2 J9U|987012500863005171‏
996 ‎‡2 BNF|12373900‏
996 ‎‡2 SUDOC|199610924‏
996 ‎‡2 LC|nr2002037297‏
996 ‎‡2 LC|n 81088528‏
996 ‎‡2 N6I|vtls000115259‏
996 ‎‡2 LC|no2017087805‏
996 ‎‡2 RERO|A003116982‏
996 ‎‡2 RERO|A003116985‏
996 ‎‡2 RERO|A003116984‏
996 ‎‡2 RERO|A003116987‏
996 ‎‡2 LC|n 92026277‏
996 ‎‡2 LC|n 2016035691‏
996 ‎‡2 SUDOC|220951241‏
996 ‎‡2 LC|n 79136644‏
996 ‎‡2 DNB|174079443‏
996 ‎‡2 J9U|987007376419105171‏
996 ‎‡2 DNB|1103505343‏
996 ‎‡2 SUDOC|081353847‏
996 ‎‡2 NUKAT|n 2021200946‏
996 ‎‡2 RERO|A012342057‏
996 ‎‡2 DNB|1057415073‏
996 ‎‡2 LC|no2021030833‏
996 ‎‡2 NTA|074493485‏
996 ‎‡2 LC|nr 89015836‏
996 ‎‡2 BAV|495_109093‏
996 ‎‡2 SUDOC|032916027‏
996 ‎‡2 BIBSYS|3077669‏
996 ‎‡2 LC|nb2001037788‏
996 ‎‡2 NII|DA0040648X‏
996 ‎‡2 LC|no 91027390‏
996 ‎‡2 NUKAT|n 2012179680‏
996 ‎‡2 BIBSYS|90233353‏
996 ‎‡2 ISNI|0000000116653493‏
996 ‎‡2 N6I|vtls000055023‏
996 ‎‡2 ISNI|000000003335560X‏
996 ‎‡2 ISNI|0000000021912632‏
996 ‎‡2 ISNI|0000000368883092‏
996 ‎‡2 N6I|vtls000854851‏
996 ‎‡2 PTBNP|1602644‏
996 ‎‡2 BIBSYS|1025709‏
996 ‎‡2 LC|no2002060985‏
996 ‎‡2 NTA|229399967‏
996 ‎‡2 J9U|987007334449005171‏
996 ‎‡2 BIBSYS|90618033‏
996 ‎‡2 NII|DA17639653‏
996 ‎‡2 NII|DA03553516‏
996 ‎‡2 BIBSYS|90184943‏
996 ‎‡2 LC|n 90629026‏
996 ‎‡2 RERO|A016565474‏
996 ‎‡2 LC|n 84161684‏
996 ‎‡2 ISNI|0000000383349226‏
996 ‎‡2 ISNI|0000000070640725‏
996 ‎‡2 BIBSYS|90361596‏
996 ‎‡2 NUKAT|n 2012241173‏
996 ‎‡2 LC|n 82127250‏
996 ‎‡2 PLWABN|9810562020705606‏
996 ‎‡2 LC|no2002064802‏
996 ‎‡2 LC|no2005092571‏
996 ‎‡2 ISNI|0000000116330766‏
996 ‎‡2 BNF|14487639‏
996 ‎‡2 LC|nb2011001866‏
996 ‎‡2 ISNI|0000000391071850‏
996 ‎‡2 DE633|pe40001646‏
996 ‎‡2 BNF|16537527‏
996 ‎‡2 DNB|1059142899‏
996 ‎‡2 NTA|160331501‏
996 ‎‡2 LC|n 80100215‏
996 ‎‡2 SUDOC|076746941‏
996 ‎‡2 LC|no2016096928‏
996 ‎‡2 ISNI|0000000506342842‏
996 ‎‡2 ISNI|0000000436795757‏
996 ‎‡2 BNF|12385283‏
996 ‎‡2 SUDOC|278657567‏
996 ‎‡2 RERO|A011244835‏
996 ‎‡2 LNB|LNC10-000057016‏
996 ‎‡2 DNB|133770834‏
996 ‎‡2 LC|n 86818079‏
996 ‎‡2 ISNI|0000000022895977‏
996 ‎‡2 LC|n 82128356‏
996 ‎‡2 BIBSYS|7057924‏
996 ‎‡2 CAOONL|ncf10152745‏
996 ‎‡2 NTA|069650829‏
996 ‎‡2 J9U|987007401409605171‏
996 ‎‡2 B2Q|0000131042‏
996 ‎‡2 J9U|987007313047005171‏
996 ‎‡2 RERO|A003116959‏
996 ‎‡2 DNB|123520282‏
996 ‎‡2 ISNI|0000000500097727‏
996 ‎‡2 NII|DA09576842‏
996 ‎‡2 LC|n 81064559‏
996 ‎‡2 ISNI|000000007382452X‏
996 ‎‡2 J9U|987007326026505171‏
996 ‎‡2 PLWABN|9810573265105606‏
996 ‎‡2 LC|n 82160079‏
996 ‎‡2 DNB|1349297542‏
996 ‎‡2 NUKAT|n 2010135675‏
996 ‎‡2 ISNI|0000000031379536‏
996 ‎‡2 J9U|987007455391005171‏
996 ‎‡2 BIBSYS|90859148‏
996 ‎‡2 ICCU|CFIV181045‏
996 ‎‡2 DNB|1029843996‏
996 ‎‡2 LC|n 82256982‏
996 ‎‡2 BNF|15071705‏
997 ‎‡a 1940 0 lived 0000 0‏ ‎‡9 1‏